Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D23A
- Development stage
- Phase 1
- Lead developer
- Triastek
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
D23A is a 3D-printed, ileum-targeted oral tablet formulation of budesonide developed by Triastek for the treatment of IgA nephropathy (IgAN). Utilizing Triastek's proprietary Melt Extrusion Deposition (MED®) and 3D Microstructure for Intestine Targeting (3DμS®-IT) platforms, the drug is designed to bypass the stomach and upper intestine, releasing the active corticosteroid specifically in the ileum. This site-specific delivery targets the Peyer's patches, which are key sites of mucosal immune response, to provide local immunomodulatory effects and reduce the production of galactose-deficient IgA1 (Gd-IgA1), a key driver of IgAN progression. In March 2024, the Chinese National Medical Products Administration (NMPA) granted IND clearance for D23A, marking it as a significant application of 3D printing technology in targeted drug delivery.
- Other names
- D23A-Triastek-OralD-23A-Triastek-OralD 23A-Triastek-Oralbudesonide ileum-targeted tablet
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on D23A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on D23A.